IP Library Granted Patent US 9,895,247
Granted Patent B2
US 9,895,247 · App. 14/679,413 · Granted Feb 20, 2018

Space-filling intragastric implants with fluid flow

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,247
App. No.
14/679,413
Granted
Feb 20, 2018
Kind
B2
Abstract

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

Claims (24)

1. A passive intragastric obesity treatment implant for placement within a stomach, comprising:

a foam body, forming a portion of an outer surface of the implant, having a sufficient outer diameter so as to contact interior walls of the stomach upon contraction thereof, the foam body having an inner diameter defining a central throughbore of the foam body:

a radially expandable and compressible stent lining the central throughbore, the stent having a tubular wall and struts across a proximal end to filter larger food particles,

the implant being formed of a material which permits it to be compressed into a substantially linear delivery configuration and that will resist degradation over a period of at least six months within the stomach,

wherein the central throughbore has a diameter between about 2-4 cm and the foam body has a thickness, measured between the outer diameter and the inner diameter, between about 6-18 cm.

2. The implant of claim 1 , wherein the foam body has an outer diameter of between about 10-20 cm.

3. The implant of claim 1 , wherein the struts extend inwardly and proximally at an angle from respective bases at the tubular wall to respective proximal ends at the proximal end of the stent, and

further comprising a ring at the proximal end of the stent joining the proximal ends of the struts together, wherein the bases of the struts are connected to the tubular wall but are not connected directly together by a ring.

4. A passive intragastric obesity treatment implant for placement within the stomach, the implant consisting of:

a radially expandable and collapsible tubular stent, the stent having a latticework tubular wall and interconnected struts that cross a proximal end of the stent and that permit radial compression and expansion and providing a filtered pathway that slows passage of food therethrough wherein the struts extend inwardly and proximally at an angle from respective bases at the tubular wall to respective proximal ends at the proximal end of the stent; and

an annular foam body, forming a portion an outer surface of the implant, surrounding the stent and having a radial size to fill a space across the stomach, and an axial size that does not extend a full length of the stomach,

the implant being formed of materials which permit it to be compressed into a substantially linear delivery configuration and that will resist degradation over a period of at least six months within the stomach

wherein the foam body has a thickness that is greater than or equal to a diameter of the central throughbore.

5. The implant of claim 4 , wherein the foam body has an outer diameter of between about 10-20 cm.

6. The implant of claim 5 , wherein the foam body defines an inner bore in which the stent is received, the inner bore having a diameter between about 2-4 cm.

7. The implant of claim 6 , wherein the foam body is annular and has a thickness between 6-18 cm.

8. The implant of claim 4 , wherein the foam body has an axial dimension of between about 10-20 cm.

9. The implant of claim 4 , wherein the stent is made from one of a rubber, fluorosilicone, fluoroelastomer, thermoplastic elastomer, thermoplastic, thermoset, metal, or any combination of the foregoing.

10. The implant of claim 4 , wherein the foam body is an open cell foam.

11. The implant of claim 4 , wherein the foam body is a closed cell foam.

12. The implant of claim 4 , wherein the foam body in a relaxed, uncompressed configuration has a cylindrical outer surface, and a cylindrical inner bore that closely receives the stent.

13. The implant of claim 12 , wherein the foam body has outwardly-projecting conical end surfaces.

14. The implant of claim 4 , wherein the foam body is made from one of a rubber, fluorosilicone, fluoroelastomer, thermoplastic elastomer, or any combination of the foregoing.

15. The implant of claim 4 , wherein the foam body defines an inner bore in which the stent is received, the inner bore having a diameter between about 2-4 cm.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2023
From: APOLLO ENDOSURGERY, INC
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 066142/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2023
From: APOLLO ENDOSURGERY US, INC.
To: APOLLO ENDOSURGERY, INC.
Reel/Frame 066142/0705 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 5, 2023
From: APOLLO ENDOSURGERY, INC.; APOLLO ENDOSURGERY US, INC.; APOLLO ENDOSURGERY INTERNATIONAL, LLC; LPATH THERAPEUTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 063264/0046 →
RELEASE OF SECURITY INTEREST Recorded Dec 30, 2021
From: SLR INVESTMENT CORP. (F/K/A SOLAR CAPITAL LTD.)
To: APOLLO ENDOSURGERY US, INC.; APOLLO ENDOSURGERY INTERNATIONAL, LLC; APOLLO ENDOSURGERY, INC.; LPATH THERAPEUTICS INC.
Reel/Frame 058599/0297 →
SECURITY INTEREST Recorded Dec 23, 2021
From: APOLLO ENDOSURGERY, INC.; APOLLO ENDOSURGERY US, INC. (F/K/A LPATH, INC.)
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 058980/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 15, 2019
From: APOLLO ENDOSURGERY US, INC.
To: SOLAR CAPITAL LTD., AS COLLATERAL AGENT
Reel/Frame 048885/0687 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 18, 2019
From: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
To: APOLLO ENDOSURGERY US, INC. (F/K/A APOLLO ENDOSURGERY, INC.)
Reel/Frame 048622/0328 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 30, 2016
From: APOLLO ENDOSURGERY US, INC.
To: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
Reel/Frame 041224/0821 →